- Home
- HROW vs ZYME Comparison
HROW vs ZYME Comparison
Compare HROW & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HROW
- ZYME
- Stock Information
- Founded
- HROW 1998
- ZYME 2003
- Country
- HROW United States
- ZYME United States
- Employees
- HROW N/A
- ZYME N/A
- Industry
- HROW Biotechnology: Pharmaceutical Preparations
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- HROW Health Care
- ZYME Health Care
- Exchange
- HROW Nasdaq
- ZYME Nasdaq
- Market Cap
- HROW 1.0B
- ZYME 983.6M
- IPO Year
- HROW N/A
- ZYME 2017
- Fundamental
- Price
- HROW $24.98
- ZYME $11.62
- Analyst Decision
- HROW Strong Buy
- ZYME Buy
- Analyst Count
- HROW 5
- ZYME 6
- Target Price
- HROW $58.40
- ZYME $19.50
- AVG Volume (30 Days)
- HROW 691.9K
- ZYME 718.6K
- Earning Date
- HROW 05-12-2025
- ZYME 05-01-2025
- Dividend Yield
- HROW N/A
- ZYME N/A
- EPS Growth
- HROW N/A
- ZYME N/A
- EPS
- HROW N/A
- ZYME N/A
- Revenue
- HROW $199,614,000.00
- ZYME $76,304,000.00
- Revenue This Year
- HROW $45.63
- ZYME $26.29
- Revenue Next Year
- HROW $38.04
- ZYME $75.78
- P/E Ratio
- HROW N/A
- ZYME N/A
- Revenue Growth
- HROW 53.32
- ZYME 0.38
- 52 Week Low
- HROW $9.86
- ZYME $7.97
- 52 Week High
- HROW $59.23
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- HROW 41.63
- ZYME 37.79
- Support Level
- HROW $25.17
- ZYME $12.15
- Resistance Level
- HROW $30.73
- ZYME $13.28
- Average True Range (ATR)
- HROW 2.18
- ZYME 0.59
- MACD
- HROW 0.20
- ZYME -0.02
- Stochastic Oscillator
- HROW 31.23
- ZYME 7.33
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.